Filtros : "Melvin, A." Limpar

Filtros



Refine with date range


  • Source: The Lancet Infectious Diseases. Unidade: FMRP

    Assunto: CRIANÇAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BABIKER, A. et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet Infectious Diseases, v. 11, n. 4, p. 273-283, 2011Tradução . . Disponível em: https://doi.org/10.1016/S1473-3099(10)70313-3. Acesso em: 27 abr. 2024.
    • APA

      Babiker, A., Castro nee Green, H., Compagnucci, A., Fiscus, S., Giaquinto, C., Gibbs, D., et al. (2011). First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet Infectious Diseases, 11( 4), 273-283. doi:10.1016/S1473-3099(10)70313-3
    • NLM

      Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibbs D, Harper L, Harrison L, Hughes HD, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS, Mussi-Pinhata MM. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial [Internet]. The Lancet Infectious Diseases. 2011 ; 11( 4): 273-283.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/S1473-3099(10)70313-3
    • Vancouver

      Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibbs D, Harper L, Harrison L, Hughes HD, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS, Mussi-Pinhata MM. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial [Internet]. The Lancet Infectious Diseases. 2011 ; 11( 4): 273-283.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/S1473-3099(10)70313-3

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024